This case highlights the risk of acute profound thrombocytopenia associated with eptifibatide use following coronary stenting.
May warrant platelet monitoring with eptifibatide post-PCI; leaves open incidence and risk factors in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Salengro et al. (2002) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: